[{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Kabuki Syndrome Foundation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Kabuki Syndrome Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Kabuki Syndrome Foundation"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Kennedy Krieger Institute","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Kennedy Krieger Institute","highestDevelopmentStatusID":"7","companyTruncated":"Oryzon Genomics \/ Kennedy Krieger Institute"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Spanish Ministry Of Science And Innovation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Spanish Ministry Of Science And Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Spanish Ministry Of Science And Innovation"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Nice & Green","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Nice & Green"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Vall d\u2019Hebr\u00f3n Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Vall d\u2019Hebr\u00f3n Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Vall d\u2019Hebr\u00f3n Hospital"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Neurology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Oryzon Genomics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Vafidemstat","moa":"LSD1\/MAO-B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Columbia University \/ Oryzon Genomics","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Oryzon Genomics"}]

Find Clinical Drug Pipeline Developments & Deals for Vafidemstat

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS-optimized LSD1 inhibitor. It is under phase 2 clinical development for the treatment of Borderline Personality Disorder (BPD).

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 03, 2025

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS-optimized LSD1 inhibitor. It is under phase 2 clinical development for the treatment of Borderline Personality Disorder (BPD).

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 10, 2024

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : The funding will advance the company's pipeline, including ORY-2001 (vafidemstat) in Phase 2b trial for the treatment of Borderline Personality Disorder.

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          November 21, 2023

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Nice & Green

                          Deal Size : $49.0 million

                          Deal Type : Financing

                          blank

                          04

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS optimized LSD1 inhibitor. Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder (PORTICO) and in schizophrenia patients (EVOLUTION).

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 26, 2023

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS optimized LSD1 inhibitor. Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder (PORTICO) and in schizophrenia patients (EVOLUTION).

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 11, 2023

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS-optimized LSD1 inhibitor. It is under phase 2 clinical development for the treatment of Borderline Personality Disorder (BPD).

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 12, 2023

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS optimized LSD1 inhibitor. Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder (PORTICO) and in schizophrenia patients (EVOLUTION).

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 07, 2023

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : ORY-2001 (vafidemstat) is an oral, CNS optimized LSD1 inhibitor. Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder (PORTICO) and in schizophrenia patients (EVOLUTION).

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 04, 2023

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : PORTICO is a multicenter, double-blind, placebo-controlled, Phase IIb trial to evaluate the efficacy and safety of ORY-2001 (vafidemstat) in adult patients. The trial has two primary independent objectives: to reduce agitation and aggression and an overa...

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 16, 2022

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Vafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects.

                          Product Name : ORY-2001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 05, 2022

                          Lead Product(s) : Vafidemstat

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Preclinical

                          Sponsor : Kennedy Krieger Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank